These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 32493345)
1. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy. Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K; BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors for intravesical recurrence after surgery for upper tract urothelial carcinoma in renal transplant recipients]. Liu YQ; Lu J; Zhao L; Hou XF; Ma LL Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):605-10. PubMed ID: 26284394 [TBL] [Abstract][Full Text] [Related]
4. Does Xylinas' nomogram accurately predict intravesical recurrence risk after radical nephroureterectomy for primary upper urinary tract urothelial carcinoma when applied to Asian populations? Lai S; Wu P; Diao T; Seery S; Liu J; Hou H; Liu M; Wang J Jpn J Clin Oncol; 2021 Mar; 51(3):469-477. PubMed ID: 32734304 [TBL] [Abstract][Full Text] [Related]
5. Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Zhong W; Zhang L; Ma J; Shao S; Lin R; Li X; Xiong G; Fang D; Zhou L Onco Targets Ther; 2017; 10():5775-5782. PubMed ID: 29255365 [TBL] [Abstract][Full Text] [Related]
6. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063 [TBL] [Abstract][Full Text] [Related]
7. Preoperative Monocyte-to-lymphocyte Ratio Predicts for Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract After Radical Nephroureterectomy Without a History of Bladder Cancer. Liu J; Wu P; Lai S; Song X; Fu C; Wang X; Liu S; Hou H; Liu M; Wang J Clin Genitourin Cancer; 2021 Jun; 19(3):e156-e165. PubMed ID: 33121908 [TBL] [Abstract][Full Text] [Related]
8. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. Fang D; Zhang L; Li X; Xiong G; Chen X; Han W; He Z; Zhou L J Cancer Res Clin Oncol; 2014 Mar; 140(3):477-85. PubMed ID: 24469253 [TBL] [Abstract][Full Text] [Related]
9. Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes. Belhadj Y; Grande P; Seisen T; Gobert A; Gomez FD; Cussenot O; Roupret M BJU Int; 2019 Apr; 123(4):618-623. PubMed ID: 30548115 [TBL] [Abstract][Full Text] [Related]
10. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation. Zhang L; Xiong G; Fang D; Li X; Liu J; Ci W; Zhao W; Singla N; He Z; Zhou L J Exp Clin Cancer Res; 2015 Jan; 34(1):5. PubMed ID: 25613404 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Balkan endemic nephropathy and gender on upper tract urothelial carcinoma outcomes after radical nephroureterectomy: A cohort study. Milojevic B; Dzamic Z; Grozdic Milojevic I; Bumbasirevic U; Santric V; Kajmakovic B; Janicic A; Durutovic O; Dragicevic D; Bojanic N; Radisavcevic D; Sipetic Grujicic S Urol Oncol; 2021 Nov; 39(11):786.e9-786.e16. PubMed ID: 34006438 [TBL] [Abstract][Full Text] [Related]
12. Risk factors and oncological outcome for intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: A propensity score-matched case control study. Jiang Y; Yao Z; Zhu X; Wu B; Bai S Int J Surg; 2020 Apr; 76():28-34. PubMed ID: 32081714 [TBL] [Abstract][Full Text] [Related]
13. Comparison of intravesical chemotherapy regimens after radical nephroureterectomy for upper tract urothelial carcinoma and analysis of risk factors for postoperative recurrence. Jiang SC; Liao YG; Luo J; Hu D; Wang YD; He K Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2387-2395. PubMed ID: 38567601 [TBL] [Abstract][Full Text] [Related]
14. The diagnostic ureteroscopy before radical nephroureterectomy in upper urinary tract urothelial carcinoma is not associated with higher intravesical recurrence. Lee HY; Yeh HC; Wu WJ; He JS; Huang CN; Ke HL; Li WM; Li CF; Li CC World J Surg Oncol; 2018 Jul; 16(1):135. PubMed ID: 29986730 [TBL] [Abstract][Full Text] [Related]
15. Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A National Multicenter Analysis. Lee CH; Ku JY; Jeong CW; Ku JH; Kwak C; Kim HH; Tae BS; Choi SH; Kim HT; Kim TH; Kwon TG; Hwang EC; Jung SI; Kang TW; Kwon DD; Ha HK Clin Genitourin Cancer; 2017 Dec; 15(6):e1055-e1061. PubMed ID: 28802888 [TBL] [Abstract][Full Text] [Related]
16. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042 [TBL] [Abstract][Full Text] [Related]
17. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677 [TBL] [Abstract][Full Text] [Related]
18. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060 [TBL] [Abstract][Full Text] [Related]
19. Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy. Kanaan N; Hassoun Z; Raggi C; Jadoul M; Mourad M; De Meyer M; Aydin S; Schmeiser HH; Cosyns JP; Goffin E Transplantation; 2016 Feb; 100(2):416-21. PubMed ID: 26457602 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]